vs
Day One Biopharmaceuticals, Inc.（DAWN）与Eventbrite, Inc.（EB）财务数据对比。点击上方公司名可切换其他公司
Eventbrite, Inc.的季度营收约是Day One Biopharmaceuticals, Inc.的1.8倍（$73.5M vs $39.8M），Eventbrite, Inc.净利率更高（-11.1% vs -49.6%，领先38.5%），Eventbrite, Inc.同比增速更快（-3.9% vs -57.6%）
Day One Biopharmaceuticals是一家临床阶段生物制药公司，专注于为患有基因驱动型癌症的儿童及年轻成人患者开发精准靶向肿瘤疗法，推进创新候选药物研发，满足相关群体未被覆盖的医疗需求，主要在美国市场开展业务。
Eventbrite是源自美国的线下活动服务平台，为用户提供活动浏览、创建与推广服务，支持主办方免费在平台发布不限规模、不限数量的各类活动，是全球范围内活跃度较高的活动交易与推广平台。
DAWN vs EB — 直观对比
营收规模更大
EB
是对方的1.8倍
$39.8M
营收增速更快
EB
高出53.7%
-57.6%
净利率更高
EB
高出38.5%
-49.6%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $39.8M | $73.5M |
| 净利润 | $-19.7M | $-8.2M |
| 毛利率 | — | 68.1% |
| 营业利润率 | -60.9% | -12.4% |
| 净利率 | -49.6% | -11.1% |
| 营收同比 | -57.6% | -3.9% |
| 净利润同比 | -153.3% | 2.5% |
| 每股收益（稀释后） | $-0.19 | $-0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DAWNEB
| Q4 25 | — | $73.5M | ||
| Q3 25 | $39.8M | $71.7M | ||
| Q2 25 | $33.9M | $72.8M | ||
| Q1 25 | $30.8M | $73.8M | ||
| Q4 24 | — | $76.5M | ||
| Q3 24 | $93.8M | $77.8M | ||
| Q2 24 | — | $84.6M | ||
| Q1 24 | $0 | $86.3M |
净利润DAWNEB
| Q4 25 | — | $-8.2M | ||
| Q3 25 | $-19.7M | $6.4M | ||
| Q2 25 | $-30.3M | $-2.1M | ||
| Q1 25 | $-36.0M | $-6.6M | ||
| Q4 24 | — | $-8.4M | ||
| Q3 24 | $37.0M | $-3.8M | ||
| Q2 24 | — | $1.1M | ||
| Q1 24 | $-62.4M | $-4.5M |
毛利率DAWNEB
| Q4 25 | — | 68.1% | ||
| Q3 25 | — | 67.9% | ||
| Q2 25 | — | 67.5% | ||
| Q1 25 | — | 66.9% | ||
| Q4 24 | — | 68.2% | ||
| Q3 24 | — | 68.5% | ||
| Q2 24 | — | 70.9% | ||
| Q1 24 | — | 71.0% |
营业利润率DAWNEB
| Q4 25 | — | -12.4% | ||
| Q3 25 | -60.9% | -1.3% | ||
| Q2 25 | -103.1% | -8.7% | ||
| Q1 25 | -133.5% | -13.2% | ||
| Q4 24 | — | -10.2% | ||
| Q3 24 | 31.6% | -11.5% | ||
| Q2 24 | — | -7.6% | ||
| Q1 24 | — | -8.8% |
净利率DAWNEB
| Q4 25 | — | -11.1% | ||
| Q3 25 | -49.6% | 8.9% | ||
| Q2 25 | -89.4% | -2.9% | ||
| Q1 25 | -117.0% | -9.0% | ||
| Q4 24 | — | -11.0% | ||
| Q3 24 | 39.5% | -4.8% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | — | -5.2% |
每股收益（稀释后）DAWNEB
| Q4 25 | — | $-0.08 | ||
| Q3 25 | $-0.19 | $0.06 | ||
| Q2 25 | $-0.29 | $-0.02 | ||
| Q1 25 | $-0.35 | $-0.07 | ||
| Q4 24 | — | $-0.09 | ||
| Q3 24 | $0.38 | $-0.04 | ||
| Q2 24 | — | $0.01 | ||
| Q1 24 | $-0.72 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $451.6M | $299.9M |
| 总债务越低越好 | — | $144.4M |
| 股东权益账面价值 | $450.9M | $179.1M |
| 总资产 | $513.8M | $647.2M |
| 负债/权益比越低杠杆越低 | — | 0.81× |
8季度趋势，按日历期对齐
现金及短期投资DAWNEB
| Q4 25 | — | $299.9M | ||
| Q3 25 | $451.6M | — | ||
| Q2 25 | $453.1M | — | ||
| Q1 25 | $473.0M | — | ||
| Q4 24 | — | $441.5M | ||
| Q3 24 | $558.4M | $24.7M | ||
| Q2 24 | — | $56.7M | ||
| Q1 24 | $317.9M | $113.7M |
总债务DAWNEB
| Q4 25 | — | $144.4M | ||
| Q3 25 | — | $174.9M | ||
| Q2 25 | — | $241.3M | ||
| Q1 25 | — | $241.0M | ||
| Q4 24 | — | $240.7M | ||
| Q3 24 | — | $240.4M | ||
| Q2 24 | — | $358.7M | ||
| Q1 24 | — | $358.2M |
股东权益DAWNEB
| Q4 25 | — | $179.1M | ||
| Q3 25 | $450.9M | $189.1M | ||
| Q2 25 | $460.8M | $177.2M | ||
| Q1 25 | $479.5M | $173.3M | ||
| Q4 24 | — | $170.2M | ||
| Q3 24 | $555.5M | $179.8M | ||
| Q2 24 | — | $176.2M | ||
| Q1 24 | $296.8M | $184.1M |
总资产DAWNEB
| Q4 25 | — | $647.2M | ||
| Q3 25 | $513.8M | $744.6M | ||
| Q2 25 | $519.0M | $784.1M | ||
| Q1 25 | $534.4M | $812.3M | ||
| Q4 24 | — | $752.3M | ||
| Q3 24 | $600.8M | $817.4M | ||
| Q2 24 | — | $894.5M | ||
| Q1 24 | $326.6M | $952.2M |
负债/权益比DAWNEB
| Q4 25 | — | 0.81× | ||
| Q3 25 | — | 0.92× | ||
| Q2 25 | — | 1.36× | ||
| Q1 25 | — | 1.39× | ||
| Q4 24 | — | 1.41× | ||
| Q3 24 | — | 1.34× | ||
| Q2 24 | — | 2.04× | ||
| Q1 24 | — | 1.95× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.8M | $-60.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-60.9M |
| 自由现金流率自由现金流/营收 | — | -82.8% |
| 资本支出强度资本支出/营收 | 0.0% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $17.6M |
8季度趋势，按日历期对齐
经营现金流DAWNEB
| Q4 25 | — | $-60.8M | ||
| Q3 25 | $-5.8M | $36.7M | ||
| Q2 25 | $-24.8M | $-17.5M | ||
| Q1 25 | $-59.0M | $59.4M | ||
| Q4 24 | — | $-45.3M | ||
| Q3 24 | $50.8M | $44.6M | ||
| Q2 24 | — | $-32.3M | ||
| Q1 24 | $-49.7M | $68.6M |
自由现金流DAWNEB
| Q4 25 | — | $-60.9M | ||
| Q3 25 | — | $36.6M | ||
| Q2 25 | $-24.8M | $-17.5M | ||
| Q1 25 | $-59.3M | $59.4M | ||
| Q4 24 | — | $-45.3M | ||
| Q3 24 | $50.0M | $44.4M | ||
| Q2 24 | — | $-32.4M | ||
| Q1 24 | — | $68.2M |
自由现金流率DAWNEB
| Q4 25 | — | -82.8% | ||
| Q3 25 | — | 51.1% | ||
| Q2 25 | -73.2% | -24.1% | ||
| Q1 25 | -192.8% | 80.4% | ||
| Q4 24 | — | -59.2% | ||
| Q3 24 | 53.4% | 57.1% | ||
| Q2 24 | — | -38.3% | ||
| Q1 24 | — | 79.1% |
资本支出强度DAWNEB
| Q4 25 | — | 0.0% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 0.0% | ||
| Q1 25 | 1.0% | 0.1% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | 0.8% | 0.2% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 0.4% |
现金转化率DAWNEB
| Q4 25 | — | — | ||
| Q3 25 | — | 5.76× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.37× | — | ||
| Q2 24 | — | -30.37× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DAWN
| Products | $38.5M | 97% |
| License Agreement With Ipsen Pharma Sas | $1.3M | 3% |
EB
| US | $52.0M | 71% |
| Other | $21.6M | 29% |
